JonesResearch analyst Soumit Roy upgraded Deciphera Pharmaceuticals to Hold from Sell without a price target. Deciphera presented positive data from the subpopulation analysis of the failed Phase 3 trial in second line gastrointestinal stromal tumors, Roy tells investors in a research note. The analyst says while Deciphera continues to remain an "interesting name with several potentially positive catalysts in the horizon," there are "multiple uncertainties" that keep him from being bullish on the name.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DCPH:
- Deciphera price target raised to $9 from $8 at Barclays
- Deciphera upgraded to Buy from Neutral at Guggenheim
- Deciphera sees FY22 revenue roughly $134M, consensus $132.52M
- Deciphera sees Q4 revenue roughly $36M, consensus $34.83M
- Deciphera announces results from ctDNA analysis from Intrigue Phase 3 trial
